Clearside Biomedical Dirección
Dirección controles de criterios 1/4
El CEO de Clearside Biomedical's es George Lasezkay , nombrado en Apr 2019, tiene una permanencia de 6.67 años. compensación anual total es $1.53M, compuesta por 34.7% salario y 65.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.51% de las acciones de la empresa, por valor de $482.29K. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 4.8 años, respectivamente.
Información clave
George Lasezkay
Chief Executive Officer (CEO)
US$1.5m
Compensación total
| Porcentaje del salario del CEO | 35.6% |
| Permanencia del CEO | 5.1yrs |
| Participación del CEO | 0.5% |
| Permanencia media de la dirección | 1.9yrs |
| Promedio de permanencia en la Junta Directiva | 4.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 06
We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate
Jun 24Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 12Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)
Aug 11Clearside Biomedical Q2 2022 Earnings Preview
Aug 08Clearside Biomedical: A Pivotal 2022 Ahead
Apr 13Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play
Dec 22Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business
Sep 30Clearside's Value Proposition Is Far From Clear
Aug 07We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth
Jun 17Clearside Biomedical climbs after positive results from early-stage wet AMD trial
Jun 15Clearside Biomedical resubmits eye treatment XIPERE NDA
May 03If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns
Feb 16Clearside Biomedical's early-stage wet AMD study gets underway
Jan 12Trade Alert: Bradford Whitmore At Clearside Biomedical, Inc. (NASDAQ:CLSD), Has Just Spent US$1m Buying 11% More Shares
Jan 12Clearside Bio drops 11% on launch of $12M direct offering
Jan 06Clearside Biomedical: SCS Microinjector Platform With Significant Upside
Jan 05Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$547k | -US$32m |
| Sep 30 2023 | n/a | n/a | -US$37m |
| Jun 30 2023 | n/a | n/a | -US$36m |
| Mar 31 2023 | n/a | n/a | -US$35m |
| Dec 31 2022 | US$2m | US$532k | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$5m |
| Jun 30 2022 | n/a | n/a | -US$2m |
| Mar 31 2022 | n/a | n/a | US$83k |
| Dec 31 2021 | US$2m | US$516k | US$376k |
| Sep 30 2021 | n/a | n/a | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$1m | US$503k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$14m |
| Jun 30 2020 | n/a | n/a | -US$18m |
| Mar 31 2020 | n/a | n/a | -US$18m |
| Dec 31 2019 | US$1m | US$385k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$49m |
| Jun 30 2019 | n/a | n/a | -US$67m |
| Mar 31 2019 | n/a | n/a | -US$82m |
| Dec 31 2018 | US$150k | n/a | -US$83m |
| Sep 30 2018 | n/a | n/a | -US$78m |
| Jun 30 2018 | n/a | n/a | -US$72m |
| Mar 31 2018 | n/a | n/a | -US$65m |
| Dec 31 2017 | US$167k | n/a | -US$59m |
Compensación vs. Mercado: La compensación total de George($USD1.53M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de George ha aumentado mientras la empresa no es rentable.
CEO
George Lasezkay (71 yo)
5.1yrs
Permanencia
US$1,538,627
Compensación
Dr. George M. Lasezkay, Pharm D, & J.D. has been Chief Executive Officer at Clearside BioMedical, Inc. since March 2020, serves as President since March 1, 2020 and served as its Interim Chief Executive Of...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 5.1yrs | US$1.54m | 0.51% $ 501.4k | |
| Chief Financial Officer | 12.3yrs | US$854.41k | 0.45% $ 442.1k | |
| Chairman of Scientific Advisory Board | 5.6yrs | US$749.87k | 0% $ 0 | |
| Head of Investor Relations | no data | sin datos | sin datos | |
| Senior Vice President of Corporate Development & Alliance Management | 1.7yrs | sin datos | sin datos | |
| Senior Vice President of Engineering & Manufacturing | 1.3yrs | sin datos | sin datos | |
| Chief Clinical Officer | 1.9yrs | sin datos | sin datos | |
| Chief Medical Officer | less than a year | sin datos | 0.040% $ 39.3k | |
| Secretary | no data | sin datos | sin datos |
1.9yrs
Permanencia media
58yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CLSD no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 6.8yrs | US$1.54m | 0.51% $ 501.4k | |
| Chairman of Scientific Advisory Board | 1.3yrs | US$749.87k | 0% $ 0 | |
| Independent Director | 12.3yrs | US$86.08k | 0.0059% $ 5.8k | |
| Independent Director | 2.2yrs | US$88.58k | 0.014% $ 13.3k | |
| Independent Director | 5.7yrs | US$88.58k | 0% $ 0 | |
| Independent Chair of the Board | 12.3yrs | US$96.08k | 0.054% $ 53.1k | |
| Member of Scientific Advisory Board | 4.1yrs | sin datos | sin datos | |
| Independent Director | 12.3yrs | US$91.71k | 0.068% $ 66.9k | |
| Member of Scientific Advisory Board | 4.1yrs | sin datos | sin datos | |
| Independent Director | 4.1yrs | US$85.46k | 0.12% $ 121.8k | |
| Independent Director | 8.3yrs | US$91.08k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.1yrs | sin datos | sin datos |
4.9yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de CLSD se considera experimentada (4.8 años de antigüedad promedio).